Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages

Shares of Precigen, Inc. (NASDAQ:PGEN) have been given an average recommendation of “Moderate Buy” by the five brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $7.00.

PGEN has been the topic of several research analyst reports. JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a report on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Precigen in a report on Thursday, January 23rd.

Institutional Investors Weigh In On Precigen

Several large investors have recently bought and sold shares of PGEN. Iridian Asset Management LLC CT increased its position in Precigen by 82.5% in the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after purchasing an additional 1,706,815 shares during the last quarter. LexAurum Advisors LLC increased its position in Precigen by 151.9% in the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 417,055 shares during the last quarter. Geode Capital Management LLC increased its position in Precigen by 4.8% during the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after acquiring an additional 149,829 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 127,467 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in Precigen by 186.8% during the third quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 125,145 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Stock Performance

PGEN stock opened at $1.96 on Friday. Precigen has a one year low of $0.65 and a one year high of $2.10. The company’s fifty day moving average price is $1.15 and its 200-day moving average price is $1.04. The company has a market capitalization of $574.03 million, a PE ratio of -3.56 and a beta of 1.66.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.